b'DISTINGUISHED INVESTIGATOR GRANTNOrexin Antagonism to Target Mechanisms of Suicide Risk: A Proof-of-Concept Clinical TrialMarianne Goodman, M.D.James J. Peters VA Medical Center$148,671Orexins are brain chemicals that regulate critical functions, such as sleep and mood. This research proposal builds on exciting genetic data identifying the orexin-1 receptor as a treatment target for suicide risk. The proposed research will study the feasibility and preliminary effect of suvorexant, an orexin receptor antagonist medication currently used for insomnia, to reduce suicide risk in suicidal Veterans with major depression. The researchers will also examine the effect of suvorexant on measures of impulsivity and aggression,which are related to vulnerability to suicide. 17'